Conover MM, Rothman KJ, Sturmer T, Ellis AR, Poole C, Jonsson Funk M. Propensity score trimming mitigates bias due to covariate measurement error in inverse probability of treatment weighted analyses: a plasmode simulation. Stat Med. 2021 Apr;40(9):2101-12. doi: 10.1002/sim.8887
Webster-Clark M, Sturmer T, Wang T, Man K, Marinac‐Dabic D, Rothman KJ, Ellis AR, Gokhale M, Lunt M, Girman C, Glynn RJ. Using propensity scores to estimate effects of treatment initiation decisions: state of the science. Stat Med. 2021 Mar 30;40(7):1718-35. doi: 10.1002/sim.8866
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012 Mar 1;12(1):2.
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Rebordosa C, Zelop CM, Kogevinas M, Sørensen HT, Olsen J. Use of acetaminophen during pregnancy and risk of preeclampsia, hypertensive and vascular disorders: a birth cohort study. J Matern Fetal Neonatal Med. 2010 May;23(5):371-8.
Garcia R, Benet M, Arnau C, Cobo E. Efficiency of the cross-over design: an empirical estimation. Stat Med. 2004 Dec 30;23(24):3773-80. doi: 10.1002/sim.2072.